Synthetic peptides corresponding to overlapping neutralizing determinants in the cbd1 epitope induce broadly neutralizing antibodies
AssigneeCentre National de la Recherche Scientifque (CNRS)
InventorsAra Hovanessian, Bernard Krust
Life of this patent
Estimating the term…
Abstract
The present invention relates to chimeric peptides having a caveolin-1 binding domain of an HIV-1 gp41 (CBD1) peptide or a variant of said CBD1, fused to a T helper epitope. In one aspect, the T epitope is from a peptide selected from the group consisting of a tetanus toxin, an HIV-1 Gag p24 and an HIV-1 Env-gp120. Compositions containing these chimeric peptides and pharmaceutical and immunogenic compositions as well as vaccines comprising these chimeric peptides also are part of the present invention. Methods to induce neutralizing antibodies against HIV-1 activity and uses of the chimeric peptides to treat or to prevent HIV-1 infection are also disclosed.
Claims25
-23. (canceled)
A chimeric peptide comprising a caveolin-1 binding domain (CBD1) of an HIV-1 gp41 peptide or a variant of said CBD1, fused to a T helper epitope.
Dependencies are inferred from the claim text.